DDInter602 DDInter1676
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dronedarone {u} (Compound) resembles {v} (Compound) Ibutilide
Dronedarone {u} (Compound) binds {v} (Gene) CACNA1F
Dronedarone {u} (Compound) causes {v} (Side Effect) Skin disorder
Dronedarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Dronedarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bisacodyl
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Dronedarone {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Dronedarone {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Dronedarone (Compound) resembles Ibutilide (Compound)
Dronedarone (Compound) binds CACNA1F (Gene)
Dronedarone (Compound) causes Skin disorder (Side Effect)
Dronedarone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Dronedarone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib
Dronedarone may lead to a major life threatening interaction when taken with Sorafenib